NCT02855944 | III | Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy) | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | California, Colorado, Georgia, Maine, Ohio, Texas |
Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
NCT02091141 | IIa | Advanced solid tumors with ALK mutations or high TMB | My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents | View Drugs | Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin |
Alectinib | ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 | ALK kinase inhibitor | Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells |
|
NCT02584478 | IIa | Recurrent ovarian cancer | A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | View Drugs | California, Florida, Louisiana, Texas |
Anlotinib | AL3818 | VEGFR2/3 kinase inhibitor | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT02419417 | IIa | Platinum resistant or refractory ovarian cancer with BRCA1/2-mutations | A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies | View Drugs | California, Colorado, Oregon, South Carolina |
BMS-986158 | BET inhibitor BMS-986158 | BET inhibitor | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02658890 | IIa | Advanced solid tumors (in expansion) | A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors | View Drugs | Arizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Missouri, New Jersey, New York, Ohio, Pennsylvania, Tennessee |
BMS-986205 | | Inhibits IDO to stimulate immune response | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02502266 | II/III | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutant ovarian cancer | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | View Drugs | Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
NCT02484404 | II | Platinum resistant or refractory ovarian cancer ( > 2 prior platinum therapies) | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | View Drugs | Maryland |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT02272998 | II | Advanced Solid Tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations | Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1) | View Drugs | Ohio |
Ponatinib | multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 | Multi-targeted kinase inhibitor |
|
NCT02079740 | II | Advanced solid tumors with KRAS or NRAS mutations (in expansion) | An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors | View Drugs | Massachusetts |
Navitoclax | Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 | Bcl-2, Bcl-XL, and Bcl-w inhibitor | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor |
|
NCT01037790 | II | Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | View Drugs | Pennsylvania |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor |
|
NCT01953926 | II | Advanced solid tumors with activating HER2 mutations | An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification. | View Drugs | Arizona, California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin |
Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor |
|
NCT02203513 | II | Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer | View Drugs | Maryland |
Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
NCT02312245 | II | Platinum resistant or refractory ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | View Drugs | Arizona, Florida, Minnesota |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
NCT02485990 | II | Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane) | An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | View Drugs | Maryland |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
NCT02568267 | II | Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | View Drugs | Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New York, North Carolina, Ohio, Oklahoma, Oregon, Texas, Utah, Virginia, Washington, Wisconsin |
Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101 | ALK, TRK, ROS1 kinase inhibitor |
|
NCT02693535 | II | Advanced solid tumors with defined molecular alterations (VEGFR, Bcr-abl, SRC, LYN, LCK, ALK, ROS1, MET,CDKN2A/p16, CDK4, CDK6, CSF1R, PDGFR, mTOR, TSC, ERBB2, BRAFV600E, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, BRCA1/BRCA2, ATM, POLD, POLE, highTMB) | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | View Drugs | Alabama, Arizona, California, Florida, Georgia, Illinois, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington |
Axitinib | Inlyta, AG-013736 | Multi-targeted RTK inhibitor | Bosutinib | Bosulif, SKI-606 | Abl and src family kinase inhibitor | Cetuximab | Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 | EGFR antagonist | Cobimetinib | Cotellic, GDC-0973, XL518 | MEK1 inhibitor | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | Dasatinib | BMS-354825, Sprycel | SRC and bcr-abl kinase inhibitor | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Olaparib | AZD2281, Lynparza | PARP inhibitor | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Sunitinib | Sunitinib malate, Sutent | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Temsirolimus | CCI-779, Torisel | mTOR inhibitor | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Vemurafenib | Zelboraf, PLX4032, RO5185426 | BRAF kinase inhibitor |
|
NCT02465060 | II | Advanced solid tumors with alterations in ALK, cKIT, EGFR, ERBB2 AMP, FGFR1-3, FGFR1-3 AMP, GNAQ, GNA11, MET, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, ROS1, SMO, TSC1/2 | Molecular Analysis for Therapy Choice (MATCH) | View Drugs | Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming |
Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | Erdafitinib | pan-FGFR tyrosine kinase inhibitor JNJ-42756493 | pan-FGFR kinase inhibitor | Larotrectinib | Trk inhibitor LOXO-101 | Pan-Trk kinase inhibitor | Osimertinib | Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib | EGFR kinase inhibitor | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Sapanisertib | TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 | TORC1/2 kinase inhibitor | Sunitinib | Sunitinib malate, Sutent | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist |
|
NCT02628067 | II | Advanced solid tumors with high MSI | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | View Drugs | California, Colorado, Florida, Maryland, Massachusetts, Minnesota, New Jersey, New Mexico, Texas |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT02576444 | II | Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations | A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors | View Drugs | Connecticut, Massachusetts, Ohio, Tennessee |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | AZD6738 | | ATR kinase inhibitor | Capivasertib | Akt inhibitor AZD5363 | pan-AKT inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT02785250 | II | Recurrent ovarian cancer | A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer | View Drugs | California, Georgia, New York, Oregon, Pennsylvania, Texas |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin | Epacadostat | 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 | Inhibits IDO to stimulate immune response |
|
NCT01325441 | II | Platinum resistant or refractory ovarian cancer (< 4 prior cytotoxic therapies) | A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | View Drugs | Indiana |
Napabucasin | cancer stemness inhibitor BBI608, BBI608 | STAT3 and cancer stemness inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT02554812 | II | Advanced solid tumors (in ovarian expansion) | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | View Drugs | California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | PD-0360324 | anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 | CSF1R antagonist and tumor-associated macrophage inhibitor | PF-04518600 | anti-OX40 antibody PF-04518600 | Stimulates OX40 to increase T cell activation and immune response |
|
NCT02832167 | II | Advanced solid tumors | An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | View Drugs | Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT01851369 | II | Advanced solid tumors and granulosa cell ovarian cancer (in expansion) | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | View Drugs | Maryland |
methoxyamine | TRC102 | Base excision repair inhibitor | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent |
|
NCT02873975 | II | Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations | A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency | View Drugs | Massachusetts |
Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity) | A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | View Drugs | Arizona, Florida, Minnesota |
MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis |
|
NCT01697527 | II | Advanced NY-ESO-1+ solid tumors | Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies | View Drugs | California |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine | | Immune response against cancer expressing NY-ESO-1 |
|
NCT02948101 | II | Platinum resistant or refractory ovarian cancer | Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | View Drugs | Texas |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | PD-0360324 | anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 | CSF1R antagonist and tumor-associated macrophage inhibitor |
|
NCT02608268 | II | Advanced solid tumors (in expansion) | Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies | View Drugs | Maryland, Massachusetts, Texas |
MBG453 | Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM3 Checkpoint Inhibitor MBG453 | Blocks TIM-3 inhibition of T cells | Spartalizumab | anti-PD-1 monoclonal antibody PDR001 | Blocks PD-L1/2 inhibition of T cells |
|
NCT02834013 | II | Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | View Drugs | Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02900560 | II | Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease) | Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | View Drugs | California, Maryland, Minnesota |
Oral Azacitidine | CC-486 | DNA methylation inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT02843165 | II | Advanced solid tumors with lesion treatable with radiotherapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | View Drugs | California |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03026062 | II | Platinum resistant or refractory ovarian cancer | Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | View Drugs | Texas |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
NCT03093155 | II | Platinum resistant, refractory or persistent ovarian cancer | A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | View Drugs | Connecticut, Maryland |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Ixabepilone | Azaepothilone B, BMS-247550, epothilone B lactam, Epothilone-B, Ixempra | Microtubule stabilizer/mitotic inhibitor |
|
NCT02920996 | II | Advanced solid tumors with NTRK1-3 rearrangements | A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements | View Drugs | Massachusetts |
Merestinib | c-Met inhibitor LY2801653, LY2801653 | Multi-targeted RTK inhibitor |
|
NCT02587598 | II | Advanced solid tumors (in expansion) | A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies | View Drugs | Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin |
Azacytidine | azacitidine, Vidaza, Mylosar, 5-AZC | DNA methylation inhibitor | INCB053914 | pan-PIM inhibitor INCB053914 | PIM1, 2, 3 inhibitor |
|
NCT03073525 | II | Advanced high grade serous, clear cell, or endometrioid ovarian cancer | A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | View Drugs | Alabama, Georgia, Montana, New Hampshire, South Carolina |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Gemogenovatucel-T | Vigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccine | Immune cell stimulator and TGFbeta inhibitor |
|
NCT03113487 | II | Platinum resistant ovarian cancer (<4 prior cytotoxic therapies) | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | California |
MVA-p53 vaccine | Modified Vaccinia Virus Ankara Vaccine Expressing p53, p53MVA, p53MVA vaccine | Immune response against p53 tumor antigen | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | View Drugs | California, Connecticut, District of Columbia, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas |
Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT03253679 | II | Advanced solid tumors with CCNE1 AMP | A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification | View Drugs | California, Colorado, Kentucky, New York, North Carolina, Pennsylvania, Texas |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor |
|
NCT03274661 | II | Advanced solid tumors | Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency | View Drugs | Florida |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03284385 | II | Advanced solid tumors with SETD2 deficiency | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | View Drugs | California, District of Columbia, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor |
|
NCT03300843 | II | Advanced solid tumors (with resectable tumor) | A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | View Drugs | Maryland |
Peptide loaded dendritic cell vaccine | | Anti-tumor immune response |
|
NCT03310879 | II | Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | View Drugs | Massachusetts |
Abemaciclib | Verzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, Bemaciclib | CDK4/6 inhibitor |
|
NCT03355976 | II | Recurrent clear cell ovarian cancer | BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | View Drugs | Rhode Island |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03342417 | II | Platinum resistant or refractory ovarian cancer | Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients | View Drugs | Georgia, New York |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03147976 | II | Advanced solid tumors with MET over-expression or mutation | A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations | View Drugs | California |
AMG 337 | | c-Met kinase inhibitor |
|
NCT03395080 | II | Platinum resistant or refractory ovarian cancer | A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer | View Drugs | Alabama, Arizona, Florida, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin |
DKN-01 | DKK1-neutralizing monoclonal antibody DKN-01 | Dickkopf-1 (DKK1) antagonist | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT01876511 | II | Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | View Drugs | California, Maryland, Ohio, Oregon, Pennsylvania |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03414047 | II | Platinum resistant or refractory high grade serous ovarian cancer | A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | View Drugs | Arizona, California, Florida, Massachusetts, Missouri, New Hampshire, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington |
Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | View Drugs | New Jersey |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | View Drugs | Michigan |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03565991 | II | Advanced solid tumors with BRCA1/2 or ATM mutations | A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors | View Drugs | California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Oklahoma, Pennsylvania, Tennessee, Texas |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
NCT03579316 | II | Platinum resistant or refractory ovarian cancer (PD on prior PARP inhibitor) | A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition | View Drugs | Massachusetts, Texas |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | View Drugs | Texas |
MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response |
|
NCT03651271 | II | Recurrent ovarian cancer with high MSI | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | View Drugs | California, Texas |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03668119 | II | Advanced solid tumors with high TMB | A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | View Drugs | California, Colorado, Florida, Illinois, Indiana, Minnesota, New Jersey, New York, North Carolina, Oregon, Tennessee, Texas |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03587311 | II | Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | View Drugs | Ohio |
Anetumab ravtansine | BAY 94-9343, Anti-mesothelin Antibody-Drug Conjugate BAY 94-9343 | ADC: anti-mesothelin + microtubule destabilizer (DM4) | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT03682289 | II | Recurrent ovarian cancer | Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies | View Drugs | California |
AZD6738 | | ATR kinase inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT03718091 | II | Advanced solid cancer with ATM truncation mutations or other HR gene mutations | A Phase II Study of M6620 (VX-970) in Selected Solid Tumors | View Drugs | Massachusetts |
Berzosertib | VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 | ATR kinase inhibitor |
|
NCT03673124 | II | Low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | View Drugs | Contact Research Staff |
Letrozole | Femara | Aromatase inhibitor | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor |
|
NCT03461952 | II | Advanced solid tumors with POLE and/or POLD1 mutations | A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay | View Drugs | New York |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03776812 | II | Platinum resistant or refractory ovarian cancer | A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Arizona |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | Relacorilant | CORT125134 | GR antagonist |
|
NCT03834220 | II | Advanced solid tumors with a FGFR1, FGFR2 or FGFR3 fusion | A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3 | View Drugs | Arizona, California, Florida, Louisiana, Maryland, Massachusetts, New Jersey, New York, North Carolina, Ohio, Texas, Washington, Wisconsin |
Debiopharm 1347 | CH5183284, FF284, FGFR Inhibitor Debio 1347 | FGFR1-3 inhibitor |
|
NCT03836352 | II | Epithelial ovarian cancer (with tumor lesions < 5 cm) | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours. | View Drugs | New York, Texas |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03684785 | Ib/II | Advanced solid tumors | A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors | View Drugs | California, Florida, Iowa, Massachusetts |
AST-008 | TLR9 agonist AST-008 | TLR agonist and immune cell stimulator | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03684811 | Ib/II | Advanced solid tumors with IDH1 mutations (inc expansion) | A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | View Drugs | Florida |
FT-2102 | | mutated IDH1 inhibitor |
|
NCT03601897 | Ib/II | Advanced solid tumors | An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | View Drugs | Alabama, New York, Oklahoma, Pennsylvania, Tennessee, Texas |
Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Rebastinib | multitargeted tyrosine kinase inhibitor DCC-2036 | Multi-targeted kinase inhibitor |
|
NCT02759588 | Ib/II | Platinum resistant, refractory or partially sensitive ovarian cancer (with peritoneal disease) | Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15) | View Drugs | California, Florida |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | GL-ONC1 | light-emitting oncolytic vaccinia virus GL-ONC1 | Membrane disrupter | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT02606305 | Ib/II | Advanced FRalpha+ ovarian cancer | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | View Drugs | Massachusetts, Ohio, Oklahoma, Pennsylvania |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Mirvetuximab Soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) |
|
NCT02511795 | Ib | Advanced solid tumors | A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours | View Drugs | Colorado, Florida, New York, Tennessee, Texas |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT02551185 | Ib | Advanced solid tumors | A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
ACY-241 | HDAC inhibitor ACY-241, histone deacetylase inhibitor ACY-241 | HDAC inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT02994953 | Ib | Advanced solid tumors | A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors | View Drugs | California, Connecticut, Florida, Louisiana, Maryland, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | NHS-IL12 | M9241, immunocytokine NHS-IL12 | IL-12 receptor agonist |
|
NCT03162562 | Ib | Recurrent or persistent ovarian cancer | Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin | View Drugs | Florida, Virginia |
Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | poly ICLC | poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC | Activates dendritic cells and induces interferon production |
|
NCT03239145 | Ib | Advanced solid tumors (inc ovarian expansion) | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | View Drugs | Massachusetts |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | Trebananib | AMG 386 | Angiopoietin 1/2 antagonist |
|
NCT03099174 | Ib | Advanced solid tumors | An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts. | View Drugs | California, Connecticut, Minnesota, Nevada, North Carolina |
Abemaciclib | Verzenio, CDK4/6 Dual Inhibitor LY2835219, LY2853219, Bemaciclib | CDK4/6 inhibitor | Xentuzumab | BI-836845 | IGF-1/2 antagonist |
|
NCT03621982 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors | View Drugs | California, Connecticut, New York, Tennessee, Texas |
Camidanlumab Tesirine | anti-CD25-PBD antibody-drug conjugate ADCT-301, ADCT-301 | DNA damaging agent |
|
NCT03586661 | Ib | Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2 WT)(inc expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | Texas |
Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Niraparib | MK4827, Zejula | PARP inhibitor |
|
NCT03589651 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | View Drugs | California, Illinois, North Carolina, Pennsylvania, Texas, Washington |
Epacadostat | 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 | Inhibits IDO to stimulate immune response | INCB050465 | PI3K-delta inhibitor INCB050465 | PI3K delta inhibitor | MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells |
|
NCT03558139 | Ib | Advanced solid tumors (inc ovarian expansion) | A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint Inhibitor Naïve Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy | View Drugs | Illinois, Michigan, Oklahoma, Texas, Washington |
Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | Hu5F9-G4 | anti-CD47 monoclonal antibody Hu5F9-G4 | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis |
|
NCT03650348 | Ib | Advanced HER2+ solid tumors (inc expansion) | A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors | View Drugs | Texas |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | PRS-343 | anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 | Immune response against cancer expressing HER2 |
|
NCT03611868 | Ib | Advanced solid tumors | A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors | View Drugs | Texas |
APG-115 | p53-HDM2 protein-protein interaction inhibitor APG-115, MDM2-p53 inhibitor APG-115 | MDM2 inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03113188 | Ib | Advanced solid tumors | Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors | View Drugs | Arizona, Louisiana, Massachusetts |
CBP501 | G2 checkpoint inhibitor CBP501 | G2 checkpoint inhibitor | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02304393 | Ib | Advanced solid tumors (in expansion) | An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors | View Drugs | |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Selicrelumab | CD40 agonist monoclonal antibody RO7009789 | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response |
|
NCT03318445 | Ib | Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion) | Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | View Drugs | California |
Irinotecan | Camptosar, Campto, Campothecin-11 | Topoisomerase I inhibitor | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
NCT03307785 | Ib | Advanced solid tumors | Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer | View Drugs | Arizona, California, Florida, Ohio, Tennessee, Texas |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Niraparib | MK4827, Zejula | PARP inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | TSR-022 | | Blocks TIM-3 inhibition of T cells | TSR-042 | ANB011, anti-PD-1 monoclonal antibody TSR-042 | Blocks PD-L1/2 inhibition of T cells |
|
NCT03168061 | Ib | Advanced solid tumors | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | View Drugs | California, Indiana, Missouri, Nevada, New York, North Carolina |
NC-6300 | epirubicin-incorporating micelle, epirubicin-conjugated polymer micelles, nanoparticle epirubicin, micellar nanoparticle-encapsulated epirubicin, K-912 | Topoisomerase II inhibitor |
|
NCT03260322 | Ib | Advanced solid tumors | A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | View Drugs | Arizona, California, Florida, Iowa, Kansas, New York, Pennsylvania, Tennessee, Virginia |
ASP8374 | PTZ-201 | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03236935 | Ib | Advanced solid tumors with high MSI or dMMR | Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer | View Drugs | Texas |
L-NMMA | pan-nitric oxide synthase inhibitor, NG-monomethyl-L-arginine | NOS inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03514121 | Ia/Ib | Advanced solid tumors (inc ovarian expansion) | A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors | View Drugs | Arizona, California, Connecticut, Michigan, Tennessee, Texas |
FPA150 | anti-B7-H4 monoclonal antibody FPA150 | Immune response against cancer expressing B7-H4, blocks B7-H4 inhibition of T cells |
|
NCT03449381 | Ia/Ib | Advanced solid tumors (inc expansion) | A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors | View Drugs | Connecticut, Florida, New York, Tennessee |
|
NCT03363776 | I/IIa | Advanced solid tumors | Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors | View Drugs | New York |
BMS-986277 | | Undisclosed mechanism | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03110107 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | Massachusetts, New Jersey, New York, Pennsylvania |
BMS-986218 | | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02913313 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | New Jersey, New York, Pennsylvania, Utah |
BMS-986207 | anti-TIGIT monoclonal antibody BMS-986207 | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02754141 | I/IIa | Advanced solid tumors | A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors | View Drugs | Maryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas |
BMS-986179 | anti-CD73 monoclonal antibody BMS-986179 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03013491 | I/II | Advanced solid tumors | An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probodyâ„¢ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas | View Drugs | Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin |
CX-072 | | Blocks PD-L1 inhibition of T cells | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Vemurafenib | Zelboraf, PLX4032, RO5185426 | BRAF kinase inhibitor |
|
NCT02953457 | I/II | Recurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancer | A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation | View Drugs | New York |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Olaparib | AZD2281, Lynparza | PARP inhibitor | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
NCT02963831 | I/II | Platinum resistant or refractory ovarian cancer (with peritoneal disease) | A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | View Drugs | Florida, New York, Ohio, Virginia |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | ONCOS-102 | | Anti-tumor immune response |
|
NCT03029598 | I/II | Platinum resistant ovarian cancer (at least 1 non-platinum therapy) | Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | View Drugs | Washington |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03251924 | I/II | Advanced solid tumors | A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | View Drugs | Massachusetts, New Jersey, Pennsylvania, Tennessee |
BMS-986226 | anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226 | Stimulates ICOS to increase T cell activity and immune response | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT02762981 | I/II | Advanced solid tumors | Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | View Drugs | Arizona, California, Illinois |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | Relacorilant | CORT125134 | GR antagonist |
|
NCT02068794 | I/II | Platinum resistant or refractory ovarian cancer | Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer | View Drugs | Minnesota |
MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis |
|
NCT02904226 | I/II | Advanced solid tumors | Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies | View Drugs | California, Colorado, Connecticut, District of Columbia, Illinois, Massachusetts, Missouri, New Jersey, New York, Tennessee, Texas, Washington |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | JTX-2011 | ICOS agonist monoclonal antibody | Stimulates ICOS to increase T cell activity and immune response | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT02671435 | I/II | Advanced solid tumors | A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors | View Drugs | Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Washington |
Cetuximab | Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 | EGFR antagonist | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Monalizumab | IPH2201, anti-NKG2A monoclonal antibody IPH2201 | Blocks HLA-E inhibition of NKG2A+ NK and cytotoxic T-lymphocytes |
|
NCT02487095 | I/II | Extrapulmonary small cell ovarian cancer | A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers | View Drugs | Maryland |
Berzosertib | VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 | ATR kinase inhibitor | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
NCT03157128 | I/II | Advanced solid tumors | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | View Drugs | California, Colorado, Georgia, Illinois, Louisiana, Massachusetts, Michigan, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Wisconsin |
LOXO-292 | RET kinase inhibitor LOXO-292 | RET-kinase inhibitor |
|
NCT03602079 | I/II | Advanced HER2+ solid tumors | A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies | View Drugs | Florida, Massachusetts, Michigan, New York, Oklahoma, Oregon, Texas, Virginia |
A166 | anti-HER2 antibody-drug conjugate A166 | ADC: anti-HER2 + cytotoxic agent |
|
NCT03407976 | I/II | Advanced solid tumors with high MSI or dMMR | A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE) | View Drugs | Utah |
Apatinib | YN968D1, Aitan, ATAN, Rivoceranib | c-Met/VEGFR2 kinase inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03564340 | I/II | Platinum resistant or refractory ovarian cancer | A Phase 1/2 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer | View Drugs | Massachusetts, New York, Ohio, Oklahoma, Tennessee |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810 | Blocks PD-L1/2 inhibition of T cells | REGN4018 | | Immune response against cancer expressing MUC16 (CA125) |
|
NCT03459222 | I/II | Advanced solid tumors | A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors | View Drugs | California, Colorado, Maryland, Missouri, Tennessee, Washington |
BMS-986205 | | Inhibits IDO to stimulate immune response | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Relatlimab | BMS986016, Anti-LAG-3 monoclonal antibody BMS-986016, Anti-LAG-3 monoclonal antibody BMS-986016 | Blocks LAG-3 inhibition of T cells |
|
NCT03729596 | I/II | Advanced solid tumors | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors | View Drugs | Michigan, North Carolina, Virginia |
MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells | MGC018 | A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload | ADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin) |
|
NCT03678883 | I/II | Advanced solid tumors | Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors | View Drugs | California, Rhode Island |
9-ING-41 | | Downregulates NF-kappaB | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Lomustine | Gleostine, CCNU | DNA damaging agent | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT03775850 | I/II | Advanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapy | A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | View Drugs | Florida, Oklahoma, Tennessee |
EDP1503 | monoclonal microbial EDP1503 | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03761914 | I/II | Recurrent or persistent WT1+ ovarian cancer | A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers | View Drugs | California |
Galinpepimut-S | | Immune response against cancer expressing WT1 | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03744468 | I/II | Advanced solid tumors | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | View Drugs | Colorado, Pennsylvania |
BGB-A425 | | Blocks TIM-3 inhibition of T cells | Tislelizumab | anti-PD-1 monoclonal antibody BGB-A317 | Blocks PD-L1/2 inhibition of T cells |
|
NCT03637764 | I/II | Platinum resistant or refractory ovarian cancer (no prior therapies for resistant/refractory disease) | A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With Atezolizumab or Isatuximab Alone in Patients With Advanced Malignancies | View Drugs | California, Massachusetts, New Jersey, Pennsylvania, Texas |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Isatuximab | anti-CD38 monoclonal antibody SAR650984 | Blocks CD38 and stimulates anti-tumor immune response |
|
NCT03665285 | I/II | Advanced solid tumors | A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | View Drugs | California, Connecticut, New Jersey, New York, Texas |
|
NCT03162627 | I/II | Recurrent ovarian cancer with Ras pathway alterations or PARP inhibitor resistance | Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance | View Drugs | Texas |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Selumetinib | AZD6244, ARRY-142886 | MEK inhibitor |
|
NCT02587962 | I/II | Advanced solid tumors | A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors | View Drugs | California, Maryland, Pennsylvania, Texas |
Birinapant | Smac Mimetic TL32711, TL32711 | SMAC mimetic and IAP antagonist | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03149549 | I/II | Advanced solid tumors | A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009) | View Drugs | California, Connecticut, Illinois, Indiana, Massachusetts, Michigan, New York, Ohio, Oregon, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin |
CX-2009 | anti-CD166 probody-drug conjugate CX-2009, PDC CX-2009, anti-CD166-DM4 CX-2009, ADC CX-2009 | ADC: anti-CD166 + microtubule destabilizer (DM4) |
|
NCT03314935 | I/II | Advanced solid tumors | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | View Drugs | Alabama, California, Georgia, Texas |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | INCB001158 | CB-1158, Arginase inhibitor | Arginase inhibitor | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
NCT03345485 | I/II | Advanced solid tumors | A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors | View Drugs | California, District of Columbia, Illinois, Michigan, New York, Texas |
Tinostamustine | EDO-S101 | HDAC inhibitor |
|
NCT03369223 | I/II | Advanced solid tumors | A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | Colorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia |
BMS-986249 | Probody of ipilumumab | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03435640 | I/II | Advanced solid tumors | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | View Drugs | Arizona, Connecticut, Florida, Georgia, New York, North Carolina, Oregon, Texas |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | NKTR-214 | | IL-2 receptor agonist | NKTR-262 | | TLR7/8 agonist and immune cell activator |
|
NCT02988817 | I/II | Advanced solid tumors | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors | View Drugs | Arizona, California, Colorado, Connecticut, Florida, Georgia, Iowa, Massachusetts, Michigan, Minnesota, New York, North Carolina, Pennsylvania, Texas, Utah, Wisconsin |
HuMax-AXL-ADC | anti-AXL monoclonal antibody-MMAE conjugate, anti-AXL/MMAE antibody-drug conjugate | ADC: anti-Axl + microtubule destabilizer (MMAE) |
|
NCT03400332 | I/II | Advanced solid tumors | A Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced Cancers | View Drugs | Colorado, Florida, Maryland, Michigan, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia |
BMS-986253 | | IL-8 antagonist | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03386526 | I/II | Advanced solid tumors | A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies | View Drugs | Texas |
APG-138 | SM-138 | SMAC mimetic and IAP antagonist | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03446040 | I/II | Advanced solid tumors | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | View Drugs | California, Colorado, Pennsylvania, Tennessee |
BMS-986258 | anti-TIM3 antibody BMS-986258 | Blocks TIM-3 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03767348 | I/II | Advanced solid tumor (with at least one injectable tumor) | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | View Drugs | Miami |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | RP1 | | Induces immune response and tumor cell lysis |
|
NCT03721679 | I/II | Advanced solid cancers | Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study | View Drugs | Maryland, New York |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | poly ICLC | poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC | Activates dendritic cells and induces interferon production |
|
NCT03829501 | I/II | Advanced solid tumors | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | View Drugs | Connecticut, Florida, New York, Tennessee, Texas |
Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | KY1044 | | Stimulates ICOS to increase T cell activity and immune response |
|
NCT03549000 | I/Ib | Advanced solid tumors (inc expansion) | A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies. | View Drugs | Texas |
NIR178 | adenosine A2A receptor antagonist NIR178 | Blocks adenosine A2A receptor inhibition of T cells | NZV930 | SRF373 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells | Spartalizumab | anti-PD-1 monoclonal antibody PDR001 | Blocks PD-L1/2 inhibition of T cells |
|
NCT02219711 | I/Ib | Advanced solid tumors with MET, AXL, RET, TRK, DDR2, KDR, PDGFRA or KIT alterations (in expansion) | A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies | View Drugs | California, Colorado, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Nebraska, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin |
Sitravatinib | MGCD516, multitargeted kinase inhibitor MGCD516 | Multi-targeted RTK inhibitor |
|
NCT03061188 | I/Ib | Advanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification) | Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes | View Drugs | Illinois |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Veliparib | ABT-888 | PARP inhibitor |
|
NCT02740270 | I/Ib | Advanced solid tumors (inc expansion) | A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas | View Drugs | New York, Texas |
GWN323 | anti-GITR monoclonal antibody GWN 323 | GITR (glucocorticoid-induced TNFR) agonist | Spartalizumab | anti-PD-1 monoclonal antibody PDR001 | Blocks PD-L1/2 inhibition of T cells |
|
NCT03013218 | I | Advanced solid tumors (inc expansion) | A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma | View Drugs | Colorado, Connecticut, Massachusetts, Michigan, Washington |
ALX148 | | Blocks CD47 signaling to stimulate immune response and tumor cell phagocytosis | Atezolizumab | RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq | Blocks PD-L1 inhibition of T cells | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist |
|
NCT02955251 | I | Advanced solid tumors (inc ovarian expansion) | A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors | View Drugs | Arizona, California, Illinois, Pennsylvania, South Carolina, Texas |
ABBV-428 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response |
|
NCT02829723 | I | Advanced solid tumors | A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors | View Drugs | Tennessee, Texas |
BLZ945 | CSF-1R inhibitor BLZ945 | CSF1R antagonist and tumor-associated macrophage inhibitor | Spartalizumab | anti-PD-1 monoclonal antibody PDR001 | Blocks PD-L1/2 inhibition of T cells |
|
NCT02611024 | I | Advanced solid tumors (inc expansion) | Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors | View Drugs | Massachusetts |
Irinotecan | Camptosar, Campto, Campothecin-11 | Topoisomerase I inhibitor | Lurbinectedin | PM01183 | |
|
NCT02070406 | I | Advanced solid tumors | NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade | View Drugs | California |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL | anti-NY-ESO-1 TCR gene-engineered lymphocytes | Immune response against cancer expressing NY-ESO-1 | NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine | | Immune response against cancer expressing NY-ESO-1 |
|
NCT02498912 | I | MUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies) | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | View Drugs | New York |
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes | 4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes | Immune response against cancer expressing CA125 | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor |
|
NCT02278250 | I | Advanced solid tumors (in ovarian expansion) | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors | View Drugs | Massachusetts, Tennessee |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | M4344 | VX-803 | ATR kinase inhibitor |
|
NCT02448589 | I | Advanced solid tumors (in expansion) | A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors | View Drugs | Ohio |
Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | TAS-119 | Aurora A kinase inhibitor TAS-119, TAS-2104 | Aurora A kinase inhibitor |
|
NCT02112565 | I | Advanced solid tumors | A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists | View Drugs | California |
COH29 | RNR inhibitor COH29, ribonucleotide reductase holoenzyme inhibitor COH29 | Ribonucleotide reductase inhibitor |
|
NCT03065387 | I | Advanced solid tumors with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation (inc expansion) | Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation | View Drugs | Texas |
Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | Neratinib | HKI-272, PD272 | EGFR, HER2, HER4 kinase inhibitor | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Trametinib | Mekinist, MEK Inhibitor GSK1120212, JTP-74057, GSK1120212, TMT212 | MEK1/2 inhibitor |
|
NCT02988960 | I | Advanced solid tumors | A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors | View Drugs | California, Illinois, Massachusetts, North Carolina, Tennessee, Texas, Virginia |
ABBV-181 | anti-PD1 monoclonal antibody ABBV-181 | Blocks PD-L1 inhibition of T cells | ABBV-927 | anti-CD40 agonist monoclonal antibody ABBV-927 | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response |
|
NCT03076372 | I | Advanced solid tumors (inc expansion) | A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors | View Drugs | Arizona, California, Minnesota, New York, North Carolina |
MM-310 | | EphA2-targeted tubulin inhibitor |
|
NCT03065062 | I | Advanced solid tumors (inc expansion) | Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | View Drugs | Massachusetts |
Gedatolisib | PKI-587, PF-05212384, dual PI3 kinase/mTOR inhibitor PKI-587 | PI3K/mTOR inhibitor | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor |
|
NCT03078400 | I | Platinum resistant or refractory CD44+ ovarian cancer (in expansion) | An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer | View Drugs | New Jersey, New York |
Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | SPL-108 | CD44 targeted agent SPL-108 | CD44 inhibitor |
|
NCT02987166 | I | Advanced solid tumors ( with palliative radiation recommended) | A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies | View Drugs | Virginia |
Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03051035 | I | Advanced solid tumors with BRAF, KRAS, NRAS or HRAS mutations | A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies | View Drugs | Minnesota, Pennsylvania |
|
NCT03071757 | I | Advanced solid tumors | A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | View Drugs | California, Connecticut, North Carolina, South Carolina, Texas, Virginia |
ABBV-368 | | Stimulates OX40 to increase T cell activation and immune response |
|
NCT03057145 | I | Advanced solid tumors | Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
Olaparib | AZD2281, Lynparza | PARP inhibitor | Prexasertib | checkpoint kinase 1 inhibitor LY2606368, LY2606368 | Chk1/2 inhibitor |
|
NCT02454010 | I | Advanced solid tumors (in ovarian expansion) | A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer | View Drugs | Texas |
FF-21101(90Y) | yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 | Radioimmunotherapy: anti-CDH3 + Y90 |
|
NCT02609230 | I | Advanced solid tumors (in expansion) | A Phase I Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma | View Drugs | Pennsylvania |
ONC201 | AKT/ERK inhibitor ONC201, TIC10 | AKT and ERK kinase inhibitor |
|
NCT03017833 | I | Advanced solid tumors (inc expansion) | Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers | View Drugs | Texas |
Metformin | Fortamet, Glucophage, Glumetza, Riomet | AMP-activated protein kinase (AMPK) activator | Sapanisertib | TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 | TORC1/2 kinase inhibitor |
|
NCT03017131 | I | Recurrent or refractory ovarian cancer | A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer | View Drugs | New York |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | Decitabine | Dacogen, dezocitidine, deoxyazacytidine, 5-aza-dCyd | DNA methylation inhibitor | Genetically Engineered NY-ESO-1-specific T Lymphocytes | | Immune response against cancer expressing NY-ESO-1 |
|
NCT02996825 | I | Platinum resistant FRalpha+ advanced ovarian cancer (< 5 prior therapies) | A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) | View Drugs | California |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Mirvetuximab Soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) |
|
NCT03030378 | I | Advanced solid tumors | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors | View Drugs | California, Colorado, Connecticut, Florida, Iowa, Maryland, Massachusetts, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Virginia |
IL-12 | cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12 | IL-12 receptor agonist | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT02972034 | I | Advanced solid tumors | A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced Malignancies | View Drugs | Michigan, Tennessee |
MK-8353 | ERK1 inhibitor MK-8353 | ERK inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03138538 | I | Advanced solid tumors | An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors | View Drugs | Connecticut, Indiana, Maryland, Michigan, New Jersey |
M8891 | Methionine Aminopeptidase 2 Inhibitor M8891 | Angiogenesis inhibitor |
|
NCT03192345 | I | Advanced solid tumors | A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With REGN2810 in Adult Patients With Advanced Solid Tumors | View Drugs | Kansas, Massachusetts, Tennessee, Texas |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, anti-PD-1 monoclonal antibody REGN2810 | Blocks PD-L1/2 inhibition of T cells | SAR439459 | anti-TGF-beta monoclonal antibody SAR-439459 | TGFbeta antagonist |
|
NCT03154281 | I | Advanced ovarian cancer (no prior PARPi) | A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer | View Drugs | South Dakota |
Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | Niraparib | MK4827, Zejula | PARP inhibitor |
|
NCT02997176 | I | Advanced solid tumors | A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Hepatic Impairment | View Drugs | California, Florida, Massachusetts, Texas |
Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
NCT03126110 | I | Advanced solid tumors | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | View Drugs | California, Florida, Michigan, Missouri, New Jersey, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Washington |
INCAGN01876 | anti-GITR agonistic monoclonal antibody INCAGN01876 | GITR (glucocorticoid-induced TNFR) agonist | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
NCT03205176 | I | Advanced solid tumors (inc ovarian expansion) | A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas | View Drugs | Florida, Oklahoma, Tennessee |
AZD5153 | | BRD4 inhibitor | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
NCT01884285 | I | Advanced solid tumors with PTEN loss/mutations or PIK3CB mutation/amplification (in expansion) | A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014 | View Drugs | Massachusetts, Michigan, New York, Washington, Wisconsin |
AZD8186 | PI3Kbeta inhibitor AZD8186 | AKT/PI3K/mTOR inhibitor |
|
NCT03249792 | I | Advanced solid tumors | A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas | View Drugs | California, Illinois, New York, Texas |
MK-2118 | | Immune cell stimulation | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
NCT03229278 | I | Advanced solid tumors | A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies | View Drugs | New Jersey |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | Trigriluzole | BHV-4157, FC-4157 | Glutamate antagonist |
|
NCT03218826 | I | Advanced solid tumors with PTEN or PIK3CB mutations (inc expansion) | A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel | View Drugs | Colorado, Maryland, New York, Texas |
AZD8186 | PI3Kbeta inhibitor AZD8186 | AKT/PI3K/mTOR inhibitor | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor |
|
NCT03096340 | I | Advanced solid tumors (inc expansion) | A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors | View Drugs | Texas, Washington |
IT-141 | | Topoisomerase I inhibitor |
|
NCT03023319 | I | Advanced solid tumors | Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | View Drugs | Ohio |
Bosutinib | Bosulif, SKI-606 | Abl and src family kinase inhibitor | Pemetrexed | Pemetrexed disodium, Alimta | DHFR and Thymidylate synthase inhibitor |
|
NCT03069469 | I | Advanced solid tumors (in expansion) | Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Malignancies | View Drugs | Colorado, Oregon, Tennessee |
DCC-3014 | | CSF1R kinase inhibitor |
|
NCT03089645 | I | Advanced solid tumors (inc expansion) | A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors | View Drugs | California, New Jersey, Rhode Island, Tennessee, Utah |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | MEDI5083 | CD40L-Fc fusion protein MEDI 5083 | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response |
|
NCT03164603 | I | Advanced solid tumors | A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors | View Drugs | Florida, New Mexico |
NLG802 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor | Inhibits IDO to stimulate immune response |
|
NCT02935907 | I | Advanced solid tumors | A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients With Advanced Solid Tumors or Lymphomas | View Drugs | Michigan, Texas |
APG-115 | p53-HDM2 protein-protein interaction inhibitor APG-115, MDM2-p53 inhibitor APG-115 | MDM2 inhibitor |
|
NCT02903771 | I | Recurrent, persistent or refractory ovarian cancer (in expansion) | Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | View Drugs | Oklahoma, Rhode Island, Texas |
Cantrixil | TRX-E-002-1 in 20% SBECD, TRX-E-002-1 | Tubulin polymerization inhibitor |
|
NCT03221400 | I | Advanced solid tumors | A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies | View Drugs | Colorado, Maryland, Tennessee |
PEN-866 | HDC SN-38, STA-12-8666 | Hsp90-targeted topoisomerase I inhibitor |
|
NCT02628574 | I | Advanced solid tumors (in expansion) | A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors | View Drugs | Illinois, New Mexico, Ohio, Pennsylvania, Tennessee |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | TRX518 | anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518 | GITR (glucocorticoid-induced TNFR) agonist |
|
NCT01239134 | I | Advanced solid tumors (in expansion) | Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose | View Drugs | New York |
TRX518 | anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518 | GITR (glucocorticoid-induced TNFR) agonist |
|
NCT03225105 | I | Advanced solid tumors (amenable to radiation treatment) | A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors | View Drugs | Indiana, Missouri, New Jersey, Pennsylvania, Tennessee |
M3541 | ATM inhibitor M 3541 | ATM kinase inhibitor |
|
NCT03237390 | I | Advanced solid tumors (inc expansion) | Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors | View Drugs | Arizona, Florida, Minnesota |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor |
|
NCT02152943 | I | Advanced ER+ and HER2+ solid tumors (in expansion) | Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance | View Drugs | Texas |
Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | Letrozole | Femara | Aromatase inhibitor | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist |
|
NCT00585195 | I | Advanced solid tumors | Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A c-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer | View Drugs | California, Colorado, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania, Vermont |
Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor |
|
NCT01877382 | I | Advanced solid tumors that are TP53 WT (in expansion) | A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas | View Drugs | Michigan, New York, Texas |
|
NCT01434316 | I | Advanced solid tumors including those with BRCA mutations (in expansion) | Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
Dinaciclib | CDK inhibitor SCH 727965, SCH 727965 | CDK1, 2, 5, 9 inhibitor | Veliparib | ABT-888 | PARP inhibitor |
|
NCT01582191 | I | Advanced solid tumors | A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer | View Drugs | Texas |
Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | Vandetanib | AZD6474, Zactima, ZD6474 | VEGFR, EGFR, and RET kinase inhibitor |
|
NCT01351103 | I | Advanced solid tumors dependent on Wnt ligands (e.g., RNF43 mutations, RSPO fusion); in expansion | A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands | View Drugs | California, Maryland, Massachusetts, Michigan, Texas |
LGK974 | PORCN inhibitor LGK974, porcupine inhibitor WNT974 | WNT ligand secretion inhibitor |
|
NCT01552434 | I | Advanced solid tumors (in expansion) | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | View Drugs | Texas |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Cetuximab | Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 | EGFR antagonist | Temsirolimus | CCI-779, Torisel | mTOR inhibitor | Valproic acid | Depacon, Depakene, Stavzor, Valproate | HDAC and NOS inhibitor |
|
NCT02052778 | I | Advanced solid tumors with FGF/FGFR alterations (in expansion) | Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations | View Drugs | Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota, New Mexico, New York, Pennsylvania, South Carolina, Texas, Washington, Wisconsin |
TAS-120 | FGFR inhibitor TAS-120 | FGFR1-4 inhibitor |
|
NCT02389309 | I | Advanced solid tumors | A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors | View Drugs | Texas |
Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | Dasatinib | BMS-354825, Sprycel | SRC and bcr-abl kinase inhibitor | Temsirolimus | CCI-779, Torisel | mTOR inhibitor |
|
NCT01591356 | I | Advanced EphA2+ solid tumors (in expansion) | EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial | View Drugs | Texas |
siRNA-EphA2-DOPC | | EphA2 inhibitor |
|
NCT02503709 | I | Advanced solid tumors | A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors | View Drugs | District of Columbia, Maryland, Massachusetts, Ohio |
AT13387 | Hsp90 inhibitor AT13387 | Hsp90 inhibitor | AT7519 | cyclin-dependent kinase inhibitor AT7519, CDKI AT7519 | CDK1, 2, 4, 6, 9 inhibitor |
|
NCT02503774 | I | Advanced solid tumors (in expansion) | A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | View Drugs | California, Connecticut, Florida, Georgia, Missouri, North Carolina, Ohio, Tennessee, Texas |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Oleclumab | anti-CD73 monoclonal antibody MEDI9447 | Blocks Ecto-5-nucleotidase (CD73) inhibition of T cells |
|
NCT02668770 | I | Advanced solid tumors (inc expansion) | A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | View Drugs | Texas |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | MGN1703 | TLR9 agonist MGN1703 | TLR9 agonist and immune cell activator |
|
NCT02534922 | I | Recurrent or persistent ovarian cancer | |